Advanced glycation urinary protein-bound biomarkers and severity of diabetic nephropathy in man

American Journal of Nephrology

Volumn 34, Issue 4, 2011, Pages 347-355

  Coughlan, Melinda T ^a,b   Patel, Sheila K ^c   Jerums, George ^c   Penfold, Sally A ^a   Nguyen, Tuong Vi ^a   Sourris, Karly C ^a   Panagiotopoulos, Sianna ^c   Srivastava, Piyush M ^c   Cooper, Mark E ^a,b   Burrell, Louise M ^c   MacIsaac, Richard J ^c   Forbes, Josephine M ^a,b,d  

^a BAKER IDI HEART AND DIABETES INSTITUTE   (Australia)

^b MONASH UNIVERSITY   (Australia)

^c UNIVERSITY OF MELBOURNE   (Australia)

^d Mater Medical Research Institute   (Australia)

Author keywords

Advanced glycation end products; Albuminuria; Carboxymethyllysine; Diabetic nephropathy; Methylglyoxal; Urinary biomarkers

Indexed keywords

6 N CARBOXYMETHYLLYSINE; ADVANCED GLYCATION END PRODUCT; ALBUMIN; METHYLGLYOXAL;

ADULT; AGED; ALBUMINURIA; ARTICLE; CONTROLLED STUDY; CROSS-SECTIONAL STUDY; DIABETIC NEPHROPATHY; DISEASE ASSOCIATION; DISEASE SEVERITY; FEMALE; GLOMERULUS FILTRATION RATE; HUMAN; INSULIN DEPENDENT DIABETES MELLITUS; MACROALBUMINURIA; MAJOR CLINICAL STUDY; MALE; MICROALBUMINURIA; NON INSULIN DEPENDENT DIABETES MELLITUS; PATIENT CODING; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; PROTEIN URINE LEVEL; TERTIARY HEALTH CARE; URINARY EXCRETION;

ADULT; ALBUMINURIA; BIOLOGICAL MARKERS; BODY MASS INDEX; COHORT STUDIES; DIABETES MELLITUS, TYPE 1; DIABETES MELLITUS, TYPE 2; DIABETIC NEPHROPATHIES; ENZYME-LINKED IMMUNOSORBENT ASSAY; FEMALE; GLOMERULAR FILTRATION RATE; GLYCOSYLATION END PRODUCTS, ADVANCED; HUMANS; MALE; MIDDLE AGED; OXIDATIVE STRESS;

EID: 80052091211     PISSN: 02508095     EISSN: 14219670     Source Type: Journal    
DOI: 10.1159/000331064     Document Type: Article

References (26)

1. Brownlee M, Cerami A, Vlassara H: Advanced glycosylation end products in tissue and the biochemical basis of diabetic complications. N Engl J Med 1988;318:1315-1321.
2. Babaei-Jadidi R, Karachalias N, Ahmed N, Battah S, Thornalley PJ: Prevention of incipient diabetic nephropathy by high-dose thiamine and benfotiamine. Diabetes 2003;52:2110-2120. (Pubitemid 36919806)
3. Coughlan MT, Thallas-Bonke V, Pete J, Long DM, Gasser A, Tong DC, Arnstein M, Thorpe SR, Cooper ME, Forbes JM: Combination therapy with the advanced glycation end product cross-link breaker, alagebrium, and angiotensin converting enzyme inhibitors in diabetes: synergy or redundancy? Endocrinology 2007;148:886-895. (Pubitemid 46143188)
4. Degenhardt TP, Alderson NL, Arrington DD, Beattie RJ, Basgen JM, Steffes MW, Thorpe SR, Baynes JW: Pyridoxamine inhibits early renal disease and dyslipidemia in the streptozotocin-diabetic rat. Kidney Int 2002;61:939-950. (Pubitemid 34175462)
5. Forbes JM, Soulis T, Thallas V, Panagiotopoulos S, Long DM, Vasan S, Wagle D, Jerums G, Cooper ME: Renoprotective effects of a novel inhibitor of advanced glycation. Diabetologia 2001;44:108-114. (Pubitemid 32141892)
6. Nakamura S, Makita Z, Ishikawa S, Yasumura K, Fujii W, Yanagisawa K, Kawata T, Koike T: Progression of nephropathy in spontaneous diabetic rats is prevented by OPB-9195, a novel inhibitor of advanced glycation. Diabetes 1997;46:895-899. (Pubitemid 27188270)
7. Soulis-Liparota T, Cooper M, Papazoglou D, Clarke B, Jerums G: Retardation by aminoguanidine of development of albuminuria, mesangial expansion, and tissue fluorescence in streptozocin-induced diabetic rat. Diabetes 1991;40:1328-1334.
8. Smedsrod B, Melkko J, Araki N, Sano H, Horiuchi S: Advanced glycation end products are eliminated by scavenger-receptormediated endocytosis in hepatic sinusoidal Kupffer and endothelial cells. Biochem J 1997;322:567-573. (Pubitemid 27116585)
9. Miyata T, Ueda Y, Horie K, Nangaku M, Tanaka S, van Ypersele de Strihou C, Kurokawa K: Renal catabolism of advanced glycation end products: the fate of pentosidine. Kidney Int 1998;53:416-422. (Pubitemid 28097858)
10. Genuth S, Sun W, Cleary P, Sell DR, Dahms W, Malone J, Sivitz W, Monnier VM: Glycation and carboxymethyllysine levels in skin collagen predict the risk of future 10-year progression of diabetic retinopathy and nephropathy in the diabetes control and complications trial and epidemiology of diabetes interventions and complications participants with type 1 diabetes. Diabetes 2005;54:3103-3111. (Pubitemid 43334362)
11. Lutgers HL, Graaff R, Links TP, Ubink-Veltmaat LJ, Bilo HJ, Gans RO, Smit AJ: Skin autofluorescence as a noninvasive marker of vascular damage in patients with type 2 diabetes. Diabetes Care 2006;29:2654-2659. (Pubitemid 44912194)
12. Wautier MP, Massin P, Guillausseau PJ, Huijberts M, Levy B, Boulanger E, Laloi-Michelin M, Wautier JL: N(carboxymethyl)lysine as a biomarker for microvascular complications in type 2 diabetic patients. Diabetes Metab 2003;29:44-52. (Pubitemid 36362615)
13. Galler A, Muller G, Schinzel R, Kratzsch J, Kiess W, Munch G: Impact of metabolic control and serum lipids on the concentration of advanced glycation end products in the serum of children and adolescents with type 1 diabetes, as determined by fluorescence spectroscopy and nepsilon-(carboxymethyl) lysine ELISA. Diabetes Care 2003;26:2609-2615. (Pubitemid 37052108)
14. Morcos M, Sayed AA, Bierhaus A, Yard B, Waldherr R, Merz W, Kloeting I, Schleicher E, Mentz S, Abd el Baki RF, Tritschler H, Kasper M, Schwenger V, Hamann A, Dugi KA, Schmidt AM, Stern D, Ziegler R, Haering HU, Andrassy M, van der Woude F, Nawroth PP: Activation of tubular epithelial cells in diabetic nephropathy. Diabetes 2002;51:3532-3544. (Pubitemid 35403461)
15. Ogawa S, Nakayama K, Nakayama M, Mori T, Matsushima M, Okamura M, Senda M, Nako K, Miyata T, Ito S: Methylglyoxal is a predictor in type 2 diabetic patients of intima-media thickening and elevation of blood pressure. Hypertension 2010;56:471-476.
16. Forbes JM, Cooper ME, Oldfield MD, Thomas MC: Role of advanced glycation end products in diabetic nephropathy. J Am Soc Nephrol 2003;14:S254-S258. (Pubitemid 36903936)
17. Humpert PM, Djuric Z, Kopf S, Rudofsky G, Morcos M, Nawroth PP, Bierhaus A: Soluble rage but not endogenous secretory rage is associated with albuminuria in patients with type 2 diabetes. Cardiovasc Diabetol 2007;6:9.
18. Tan KC, Shiu SW, Chow WS, Leng L, Bucala R, Betteridge DJ: Association between serum levels of soluble receptor for advanced glycation end products and circulating advanced glycation end products in type 2 diabetes. Diabetologia 2006;49:2756-2762.
19. Norman PE, Davis WA, Coughlan MT, Forbes JM, Golledge J, Davis TM: Serum carboxymethyllysine concentrations are reduced in diabetic men with abdominal aortic aneurysms: Health in Men Study. J Vasc Surg 2009;50:626-631.
20. Friess U, Waldner M, Wahl HG, Lehmann R, Haring HU, Voelter W, Schleicher E: Liquid chromatography-based determination of urinary free and total N(epsilon)-(carboxymethyl)lysine excretion in normal and diabetic subjects. J Chromatogr B Analyt Technol Biomed Life Sci 2003;794:273-280. (Pubitemid 37101004)
21. Penfold SA, Coughlan MT, Patel SK, Srivastava PM, Sourris KC, Steer D, Webster DE, Thomas MC, MacIsaac RJ, Jerums G, Burrell LM, Cooper ME, Forbes JM: Circulating high-molecular-weight rage ligands activate pathways implicated in the development of diabetic nephropathy. Kidney Int 2010;78:287-295.
22. Requena JR, Fu MX, Ahmed MU, Jenkins AJ, Lyons TJ, Thorpe SR: Lipoxidation products as biomarkers of oxidative damage to proteins during lipid peroxidation reactions. Nephrol Dial Transplant 1996;11(suppl 5):48-53. (Pubitemid 27062911)
23. Miura J, Yamagishi S, Uchigata Y, Takeuchi M, Yamamoto H, Makita Z, Iwamoto Y: Serum levels of non-carboxymethyllysine advanced glycation endproducts are correlated to severity of microvascular complications in patients with type 1 diabetes. J Diabetes Complications 2003;17:16-21. (Pubitemid 36042787)
24. Berg TJ, Snorgaard O, Faber J, Torjesen PA, Hildebrandt P, Mehlsen J, Hanssen KF: Serum levels of advanced glycation end products are associated with left ventricular diastolic function in patients with type 1 diabetes. Diabetes Care 1999;22:1186-1190. (Pubitemid 29293975)
25. Nin JW, Jorsal A, Ferreira I, Schalkwijk CG, Prins MH, Parving HH, Tarnow L, Rossing P, Stehouwer CD: Higher plasma levels of advanced glycation end products are associated with incident cardiovascular disease and allcause mortality in type 1 diabetes: a 12-year follow-up study. Diabetes Care;34:442-447.
26. Wagner Z, Wittmann I, Mazak I, Schinzel R, Heidland A, Kientsch-Engel R, Nagy J: N(epsilon)-(carboxymethyl)lysine levels in patients with type 2 diabetes: role of renal function. Am J Kidney Dis 2001;38:785-791.